HUYA Bioscience International

HUYA Bioscience International

HUYA Bioscience International is a San Diego-based company founded by Mireille Gillings.

Founded in 2004, HUYA Bioscience International is a bio-science and biopharmaceutical company which works to identify and license pre-clinical and clinical-stage compounds coming out of China to leverage and extend research efforts and provide a bridge into international development. Through their model, HUYA tries to accelerate development while lowering business risk in introducing new compounds.

Compounds

HBI-8000

HBI-8000 is an orally taken, epigenetic drug, and a member of the benzamide class of histone deacetylase inhibitors which works to control how tightly DNA is wound around a histone protein. HBI-8000 looks to have immunomodulatory effects regulating antitumor activity and repression of genes associated with drug resistance. The product is currently undergoing a Phase II trial in the US to investigate efficacy and safety.

HBI-3000

HBI-3000 is an intravenous infusion administered multi-ion channel blocker treating atrial fibrillation. The compound is currently in Phase 1 testing.

HBI-3802

HBI-3802 is a small molecule with regenerative properties in cardiac muscle cells and possibly used after myocardial infarction, heart attacks, to strengthen and build the cardiac muscle. The compound stimulates cell differentiation into functional cardiomyocytes, replacing and remodeling dead myocardium with new functional tissue.

Funding

Venture Equity

HUYA Bioscience raised $5 million in April 2009. None of the investors were announced.

Debt Equity

In March of 2012, HUYA Bioscience raised $7.6 million in equity and debt financing. Investors were not announced. $3 million of the financing was through convertible promissory notes.

Debt Financing

HUYA Bioscience raised $48 million in debt financing in April 2015. Investors were not announced. The total amount raised was offered in convertible promissory notes.

Timeline

People

Name
Role
LinkedIn

Chen Yao, MD

Advisor

Christopher Kemmerer, PhD

Vice President, Chemistry, Manufacturing and Controls

Chun-Lin Chen, PhD, EMBA

Advisor

Clement Gingras

Chief Technology Officer and Chief Operating Officer Asia

Curtis Tyree, PhD

Senior Vice President, Strategic Planning

Gloria Lee, MD, PhD

Chief Medical Officer

Guozhong Rui, PhD

Advisor

Hiroshi Onogi, MD

Executive Vice President, Head of Clinical Development - Japan

Jin Li, MD

Advisor

Jonathan O'Connell

Chief Financial Officer

Jun Sun, PhD

Vice President, Business Development - China

Ken Nanami

Director, Clinical Operations

Kenneth D. Polin, Esq.

Chief Administrative Officer and General Counsel

Martin Doorbar

Global Head CMC and Manufacturing Operations

Masutoshi Toya

Clinical Project Management Director

Mireille Gillings, PhD, Hon DSc

CEO and Executive Chair

Qishan Wang, PhD

Director Shanghai Office, East China

Reid Bissonnette, PhD

Vice President, Pharmacology

Robert Goodenow, PhD

President

Rulun Zhou, MD, MS

Senior Director Beijing Office, North China

Shawn Shao-Hui Zhang, PhD

Advisor

Shun Lu, MD, PhD

Advisor

Suzanne Romano, PhD

Vice President, Product Evaluation & Early Stage Development

Xiaoping Ye, DPhil, EMBA

Advisor

Xinhui Luan, PhD

Advisor

Page 1 of 2

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.